Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, randomized controlled study meant to test the superior
efficacy of oral anticoagulation (OAC) therapy versus double antiplatelet therapy (DAPT) in
patients after TAVR. Patients who accept successful TAVR will be randomized to receive either
the OAC group (Vitamin-K antagonists) or the DAPT group (aspirin and clopidogrel) for 6
months on a 1:1 ratio. After that, patients from both groups will be treated with single
antiplatelet therapy (aspirin). All patients will be followed for 1 year to test the
difference between net clinical benefits and prosthetic valve thrombosis diagnosed by 4D-CT.